MCD
MCID: KPS004
MIFTS: 67

Kaposi Sarcoma (MCD) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Blood diseases, Neuronal diseases

Aliases & Classifications for Kaposi Sarcoma

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Kaposi Sarcoma:

Name: Kaposi Sarcoma 52 11 48 54 50 13 68
Kaposi's Sarcoma 11 48 38 13
Angiofollicular Ganglionic Hyperplasia 54 68
Kaposi Sarcoma, Susceptibility to 52 12
Kaposi's Sarcoma of Soft Tissue 11 68
Kaposi's Sarcoma of Palate 11 68
Kaposi's Sarcoma of Lung 11 68
Kaposi's Sarcoma of Gastrointestinal Sites 11
Kaposi's Sarcoma of Central Nervous System 11
Multicentric Giant Lymph Node Hyperplasia 54
African Lymphadenopathic Kaposi's Sarcoma 11
Central Nervous System Kaposi's Sarcoma 11
Kaposi's Sarcoma-Associated Herpesvirus 11
Kaposi's Sarcoma of the Gallbladder 11
Lymphadenopathic Kaposi's Sarcoma 11
Multi-Centric Castleman's Disease 68
Angiofollicular Lymph Hyperplasia 54
Kaposi's Sarcoma of Soft Tissues 11
Kaposi's Sarcoma of the Prostate 11
Kaposi's Sarcoma of Conjunctiva 11
Kaposi's Sarcoma of Lymph Nodes 11
Non-Aids-Related Kaposi Sarcoma 68
Non Aids Related Kaposi Sarcoma 48
Multicentric Castleman Disease 54
Conjunctival Kaposi's Sarcoma 11
Kaposi's Sarcoma of Esophagus 11
Soft Tissue Kaposi's Sarcoma 11
Mediterranean Kaposi Sarcoma 48
Gallbladder Kaposi's Sarcoma 11
 
Intestinal Kaposi's Sarcoma 11
Kaposi's Sarcoma of the Cns 11
Lymph Node Kaposi's Sarcoma 11
Esophageal Kaposi's Sarcoma 11
Kaposi Sarcoma Herpesvirus 48
Pulmonary Kaposi's Sarcoma 11
Cutaneous Kaposi's Sarcoma 11
Kaposi's Sarcoma of Cornea 11
Kaposi's Sarcoma of Penis 11
Kaposi's Sarcoma of Heart 11
Prostate Kaposi's Sarcoma 11
Angiolymphoid Hyperplasia 68
Kaposi's Sarcoma of Skin 11
Corneal Kaposi's Sarcoma 11
Cardiac Kaposi's Sarcoma 11
Gastric Kaposi's Sarcoma 11
Kaposi's Sarcoma of Anus 11
Palate Kaposi's Sarcoma 11
Penis Kaposi's Sarcoma 11
Kaposi's Sarcoma, Skin 11
Kaposi's Sarcoma, Lung 11
Anal Kaposi's Sarcoma 11
Human Herpesvirus 8 48
Castleman Disease 54
Sarcoma, Kaposi 39
Hhv8 48
Kshv 48
Mcd 54

Characteristics:

Orphanet epidemiological data:

54
kaposi sarcoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult
angiofollicular ganglionic hyperplasia:
Inheritance: Not applicable; Age of onset: All ages

HPO:

64
kaposi sarcoma:
Inheritance: autosomal dominant inheritance

Classifications:



Summaries for Kaposi Sarcoma

About this section
NIH Rare Diseases:48 Kaposi sarcoma (ks) is a cancer that develops from the cells that line lymph or blood vessels. it usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). the abnormal cells of kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. these lesions may look bad, but they usually cause no symptoms. however, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. kaposi sarcoma is caused by infection with a virus called the kaposi sarcoma associated herpesvirus (kshv), also known as human herpesvirus 8 (hhv8). kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-saharan indigenous africans), iatrogenic (associated with immunosuppressive drug therapy) and aids-associated (epidemic ks). options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy (immunotherapy). the main aim is to restore immunity. last updated: 2/4/2016

MalaCards based summary: Kaposi Sarcoma, also known as kaposi's sarcoma, is related to angiofollicular lymph hyperplasia and endemic kaposi sarcoma, and has symptoms including exanthema, pruritus and fever. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways are IL6-mediated signaling events and Cytokine production by Th17 cells in CF (Mouse model). The drugs etoposide and etoposide phosphate have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and skin, and related mouse phenotypes are liver/biliary system and cellular.

Disease Ontology:11 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in formation of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

OMIM:52 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with... (148000) more...

MedlinePlus:38 Kaposi's sarcoma (ks) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. these patches, or lesions, are usually red or purple. they are made of cancer cells, blood vessels, and blood cells. ks is caused by infection with human herpesvirus-8 (hhv-8). most people infected with hhv-8 don't get ks. it usually happens in people with weak immune systems, due to hiv/aids, drugs taken after an organ transplant, or another disease older men of jewish or mediterranean descent young men in africa the skin lesions may not cause symptoms. but they can spread to other parts of the body, especially in people with hiv/aids. if they spread to the digestive tract or lungs, they can cause bleeding. lesions on the lungs can also make it hard to breathe. treatment depends on where the lesions are and how bad they are. options include radiation therapy, surgery, chemotherapy, and biologic therapy. people with hiv/aids also take hiv/aids medicines. nih: national cancer institute

Related Diseases for Kaposi Sarcoma

About this section

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 137)
idRelated DiseaseScoreTop Affiliating Genes
1angiofollicular lymph hyperplasia12.2
2endemic kaposi sarcoma12.2
3colon kaposi sarcoma12.0
4human herpesvirus 811.8
5immunodeficiency 1611.7
6unicentric castleman disease11.2
7rectum kaposi's sarcoma11.0
8sarcoma10.9
9bipolar i disorder10.3FGF2, IL6, VEGFA
10vitreoretinopathy, neovascular inflammatory10.3IL6, IL6R, IL6ST
11lymphoma10.3
12pyriform sinus cancer10.3FGF2, IL6, VEGFA
13benign idiopathic neonatal seizures10.3FGF2, KDR, VEGFA
14vesiculobullous skin disease10.3FLT4, KDR, VEGFA
15thyroid angiosarcoma10.3CD34, VEGFA
16urinary bladder posterior wall cancer10.3FGF2, IL6, VEGFA
17castleman disease10.3
18multicentric castleman disease10.3
19neurilemmoma of the pleura10.3FGF2, KDR, VEGFA
20spinocerebellar ataxia 2510.3IL6, KDR, VEGFA
21factitious disorder10.3FLT4, KDR, VEGFA
22congenital disorder of glycosylation, type iq10.3FGF2, IFNA1, IFNA2
23vulvitis10.3IL6, KDR, VEGFA
24subdural empyema10.3FGF2, KDR, VEGFA
25keratosis follicularis spinulosa decalvans10.3CD34, FLT4, KDR
26hypomelanosis of ito10.3FLT4, IFNA2
27circumscribed cutaneous aplasia of the vertex10.3CD34, IFNA1, IFNA2
28oppositional defiant disorder10.3FGF2, IL6, KDR, VEGFA
29pilomyxoid astrocytoma10.3FLT4, IFNA2
30anterograde amnesia10.3FGF2, IL6, VEGFA
31human granulocytic anaplasmosis10.3FLT4, KDR, VEGFA
32orofaciodigital syndrome 1310.3FLT4, PDPN
33malignant glioma10.2IFNA1, IFNA2
34craniosynostosis, type 110.2IL6, VEGFA
35grade iii astrocytoma10.2FGF2, IL6, KDR, VEGFA
36anterior foramen magnum meningioma10.2CD34, IFNA1, IFNA2, IL6
37gestational choriocarcinoma10.2CD34, FGF2, VEGFA
38neuropathy, hereditary sensory, type ib10.2FGF2, KDR, VEGFA
39familial acute necrotizing encephalopathy10.2IFNA1, IFNA2, PDPN
40primary effusion lymphoma10.2
41phencyclidine abuse10.2CD34, FLT4, PDPN
42citrullinemia, type ii, neonatal-onset10.2FGF2, KDR, VEGFA
43uterine benign neoplasm10.2CD34, FGF2, PDPN
44conventional leiomyosarcoma10.2CD34, FGF2, PDPN
45ceruminoma10.2IFNA1, IFNA2
46acquired immunodeficiency syndrome10.2
47hyperpituitarism10.2CD34, FGF2, PDPN
48senile cataract10.2IFNA1, IFNA2, IL6
49lymphoma, large-cell, immunoblastic10.2FLT4, KDR, PDPN
50cutis laxa, autosomal recessive, type ib10.2CD34, IFNA1, IL6, IL6R, VEGFA

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to kaposi sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

About this section

Symptoms by clinical synopsis from OMIM:

148000

Clinical features from OMIM:

148000

Human phenotypes related to Kaposi Sarcoma:

 54 64 (show all 28)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 susceptibility to herpesvirus64 54 Obligate (100%) HP:0005353
2 hypermelanotic macule64 54 Very frequent (99-80%) HP:0001034
3 abnormality of the lower limb64 54 Very frequent (99-80%) HP:0002814
4 neoplasm of the skin64 54 Very frequent (99-80%) HP:0008069
5 macule54 Very frequent (99-80%)
6 abnormality of the retina64 54 Frequent (79-30%) HP:0000479
7 hemangioma64 54 Frequent (79-30%) HP:0001028
8 encephalopathy64 54 Frequent (79-30%) HP:0001298
9 abnormality of the spleen64 54 Frequent (79-30%) HP:0001743
10 immunodeficiency64 54 Frequent (79-30%) HP:0002721
11 lymphoproliferative disorder64 54 Frequent (79-30%) HP:0005523
12 generalized lymphadenopathy64 54 Frequent (79-30%) HP:0008940
13 abnormality of the gastrointestinal tract64 54 Frequent (79-30%) HP:0011024
14 papule64 54 Frequent (79-30%) HP:0200034
15 skin nodule64 54 Frequent (79-30%) HP:0200036
16 skin rash64 54 Occasional (29-5%) HP:0000988
17 lymphedema64 54 Occasional (29-5%) HP:0001004
18 abnormality of the liver64 54 Occasional (29-5%) HP:0001392
19 weight loss64 54 Occasional (29-5%) HP:0001824
20 fever64 54 Occasional (29-5%) HP:0001945
21 diarrhea64 54 Occasional (29-5%) HP:0002014
22 abnormality of lung morphology64 54 Occasional (29-5%) HP:0002088
23 venous insufficiency64 54 Occasional (29-5%) HP:0005293
24 neoplasm by anatomical site54 Occasional (29-5%)
25 fatigue64 54 Occasional (29-5%) HP:0012378
26 skin plaque64 54 Occasional (29-5%) HP:0200035
27 edema64 HP:0000969
28 neoplasm64 HP:0002664

UMLS symptoms related to Kaposi Sarcoma:


exanthema, pruritus, fever

MGI Mouse Phenotypes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537010.0CDK6, FLT4, IL6, IL6R, IL6ST, KDR
2MP:00053849.5CD34, CDK6, FGF2, FGF4, IL6, IL6R
3MP:00107719.3CD34, FGF5, FLT4, IL6, IL6ST, KDR
4MP:00020069.2CD34, CDK6, FGF2, IL6, IL6R, IL6ST
5MP:00053979.2CD34, CDK6, FGF2, IL6, IL6R, IL6ST
6MP:00053769.2CD34, FGF2, FLT4, IL6, IL6R, IL6ST
7MP:00053878.9CCR8, CD34, CDK6, FLT4, IL6, IL6R

Drugs & Therapeutics for Kaposi Sarcoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Doxil16 44 DOXORUBICIN HYDROCHLORIDE Alza June 1999
FDA Label: Doxil
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:16 DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:14 1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:16 
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
2
Intron A16 44 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
FDA Label: Intron A
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:16 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkin’s Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:14 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:16 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
3
Taxol16 44 PACLITAXEL Bristol-Myers Squibb August 1997
FDA Label: Taxol
Disease/s that Drug Treats:Kaposi's Sarcoma
Indications and Usage:16 Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma ofthe ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin.Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast canceradministered sequentially to standard doxorubicin-containing combination chemotherapy.. In the clinicaltrial, there was an overall favorable effect on disease-free and overall survival in the total population ofpatients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen andprogesterone receptor-negative tumors (see CLINICAL STUDIES, Breast Carcinoma).Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combinationchemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapyshould have included an anthracycline unless clinically contraindicated.Paclitaxel Injection, USP, in combination with cisplatin, is indicated for the first-line treatment of nonsmallcell lung cancer in patients who are not candidates for potentially curative surgery and/or radiationtherapy.Paclitaxel Injection, USP is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.
DrugBank Targets:14 1. Apoptosis regulator Bcl-2;2. Tubulin beta-1 chain;3. Nuclear receptor subfamily 1 group I member 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein 2;6. Microtubule-associated protein tau
Mechanism of Action:16 
Target: microtubules
Action: promoter of assembly & preventor of depolymerization
FDA: Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulindimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibitionof the normal dynamic reorganization of the microtubule network that is essential for vital interphase andmitotic cellular functions. In addition, paclitaxel induces abnormal arrays or “bundles” of microtubulesthroughout the cell cycle and multiple asters of microtubules during mitosis.Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in abiphasic manner. The initial rapid decline represents distribution to the peripheral compartment andelimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from theperipheral compartment.Pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levelsof 135 and 175 mg/m2 were determined in a Phase 3 randomized study in ovarian cancer patients and aresummarized in the following table:

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 196)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Efavirenzapproved, investigationalPhase 4, Phase 3409154598-52-464139
Synonyms:
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-Efavirenz
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
154598-52-4
1ikv
1ikw
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9
6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
AC-19049
AC1L20IX
BIDD:GT0383
C08088
C14H9ClF3NO2
CHEBI:119486
CHEMBL223228
CID64139
CPD000466351
D00896
DB00625
DB07709
DMP 266
DMP-266
EFV
 
EFZ
Efavirenz
Efavirenz (JAN/INN)
Efavirenzum
Eravirenz
HMS2051J08
HMS2090N16
HSDB 7163
L 743726
L-741211
L-743,726
L-743725
L-743726
LS-173464
MLS000759465
MLS001424087
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MolPort-003-983-924
NSC742403
SAM001246667
SBB066062
SMR000466351
Stocrin
Strocin (TM)
Sustiva
Sustiva (TM)
Sustiva (TN)
UNII-JE6H2O27P8
ZINC02020233
efavirenz
efavirenz, (S)-isomer
zoxazin-2-one
Éfavirenz
2
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
3
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 19222068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
4
BleomycinapprovedPhase 4, Phase 3, Phase 2, Phase 115911056-06-75360373
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
BLM
Blenoxane
Bleo
Bleocin
Bleogin
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin A(2)
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin B(2)
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
 
Bleomycine
Bleomycine [INN-French]
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
LMPK14000006
LS-44860
LS-524
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
bleomycin
bleomycin a2
5
Ritonavirapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1883155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
6
Valganciclovirapproved, investigationalPhase 4, Phase 283175865-60-864147
Synonyms:
175865-60-8
5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
AC1L20JF
AC1Q63EV
C14H22N6O5
CID64147
Cymeval
D02495
DB01610
I06-1704
L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester
L-Valine, ester with ganciclovir
 
L-valine, ester with ganciclovir
LS-173677
NCGC00168779-01
RO1079070/194
RS 79070
UNII-GCU97FKN3R
Valcyt
Valcyte
Valganciclovir
Valganciclovir (INN)
Valganciclovir (Oral)
Valganciclovir [INN:BAN]
[2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
valganciclovir
7
Ganciclovirapproved, investigationalPhase 4, Phase 215382410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3
8
Tenofovirapproved, investigationalPhase 4, Phase 3759147127-20-6464205
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-9-(2-phosphonomethoxypropyl)adenine
(R)-PMPA
147127-20-6
206184-49-8
AC-760
AC1LA9BO
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
GNA & Tenofovir
GS 1275
GS 1278
GS1278
 
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
PMPA
PMPA-(R)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
S1401_Selleck
TDF
TFV
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir disoproxil
Tenofovir disoproxil fumarate
UNII-99YXE507IL
Viread
Viread, Tenofovir
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
9
LopinavirapprovedPhase 4, Phase 2, Phase 3344192725-17-092727
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
A 157378
A 157378.0
A-157378-0
A-157378.0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
AC1L3OPJ
AIDS032937
 
Aluviran
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Koletra
LPV
LS-173766
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
10
Stavudineapproved, investigationalPhase 41723056-17-518283
Synonyms:
1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2
132425-31-1
2',3' Didehydro 3' deoxythymidine
2',3'-Anhydrothymidine
2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI)
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor
3'-Deoxy-2',3'-didehydrothymidine
3'-Deoxy-2'-thymidinene
3056-17-5
AC-5263
AC1L2BQ9
AC1Q6BSH
BB_NC-1008
BIDD:GT0082
BMY 27857
BMY-27857
BMY27857
BRN 0618327
Bristol-Myers Brand of Stavudine
Bristol-Myers Squibb Brand of Stavudine
C07312
CHEBI:207119
CHEMBL991
CID18283
CPD000058350
CPD000673569
D 1413
D 4T
D 4T (nucleoside)
D00445
D018119
D1413_SIGMA
D3580
D4T & GM-CSF
D4TMBY-27857-3
DB00649
Dideoxydidehydrothymidine
EU-0100336
Estavudina
Estavudina [INN-Spanish]
FT-0082665
 
HMS2051O20
HSDB 7338
LS-1160
Lopac0_000336
MLS000028546
MLS000759504
MLS001055348
MLS001077292
MolPort-002-507-283
NCGC00023212-03
NCGC00023212-04
NCGC00023212-05
NCGC00023212-07
NCGC00023212-08
NCGC00023212-09
NCGC00023212-10
NSC 163661
NSC163661
SAM001246729
SAM002589948
SMR000058350
SMR000673569
STK801888
STV
Sanilvudine
Sanilvudine (JAN)
Stavudin
Stavudine
Stavudine (USAN/INN)
Stavudine [USAN:BAN:INN]
Stavudine [USAN:INN:BAN]
Stavudine [Usan:Ban:Inn]
Stavudine, Monosodium Salt
Stavudinum
Stavudinum [INN-Latin]
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI)
UNII-BO9LE4QFZF
ZINC00137884
Zent
Zerit
Zerit (TN)
Zerit XR
Zerit Xr
Zerit(TM)
Zerut XR
d4T
ddeThd
ddeTyd
sanilvudine
stavudine
11
Emtricitabineapproved, investigationalPhase 4, Phase 3457143491-57-060877
Synonyms:
(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-FTC
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-Fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-amino-5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
524W91
AC1L1U3I
AC1Q4KUB
BW 1592
 
BW 524W91
BW-524W91
BW524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
RCV
Racivir
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
dOTFC
emtricitabine
12
NevirapineapprovedPhase 4, Phase 3223129618-40-24463
Synonyms:
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
129618-40-2
1vrt
2hny
AC-643
AC1L1I81
BI RG 587
BI-RG-587
BI-RG-587 & CD4-IgG
BIDD:GT0326
BIRG 0587
BIRG 587
BIRG-0587
BIRG-587
BIRG587
Bio-0789
C07263
C15H14N4O
CHEBI:44659
CHEMBL57
CID4463
CPD000048458
Cahill May Roberts Brand of Nevirapine
D00435
D019829
DB00238
DB08311
 
HMS2051J09
HSDB 7164
I02-0310
LS-2289
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MolPort-002-507-817
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NCGC00065890-02
NEV
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NSC 641530
NSC641530
NVP
Nevirapine
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine (JAN/USP/INN)
Nevirapine [USAN:INN]
Promeco Brand of Nevirapine
S1742_Selleck
SAM001246551
SMR000048458
STK580320
UNII-99DK7FVK1H
Viramune
Viramune (TN)
Viramune(TM)
Viramune, BI-RG 587, Nevirapine
ZINC00004778
nevirapine
13
Lamivudineapproved, investigationalPhase 4, Phase 2, Phase 3621134678-17-460825
Synonyms:
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-SddC
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
3'-Thia-2',3'-dideoxycytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
480434-79-5
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH-189
BCH-790
BCH189
BIDD:GT0033
Bio-0652
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
 
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR-109714X
GR109714X
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
Hepitec
Heptivir
Heptodin
Heptovir
L0217
LMV
LS-2107
Lamivir
Lamivudin
Lamivudina
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-Isomer
Lamivudinum
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
ZINC00012346
Zeffix
Zefix
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
lamivudine
14
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
15
protease inhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 15471
Synonyms:
 
protease inhibitors
16Anti-Retroviral AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13296
17Anti-Infective AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 122062
18HIV Protease InhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 15470
19Anti-HIV AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13162
20Antiviral AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 19967
21AntimetabolitesPhase 4, Phase 2, Phase 3, Phase 112054
22Ganciclovir triphosphatePhase 4, Phase 2153
23Cytochrome P-450 CYP2C9 InhibitorsPhase 4, Phase 3669
24Emtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationPhase 4, Phase 3248
25Cytochrome P-450 CYP3A InhibitorsPhase 4, Phase 2, Phase 31715
26Reverse Transcriptase InhibitorsPhase 4, Phase 2, Phase 3, Phase 11913
27Nucleic Acid Synthesis InhibitorsPhase 4, Phase 2, Phase 3, Phase 14962
28Cytochrome P-450 CYP3A InducersPhase 4, Phase 31119
29Cytochrome P-450 Enzyme InhibitorsPhase 4, Phase 2, Phase 33917
30
Paclitaxelapproved, vet_approvedPhase 3, Phase 2286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
31
Meloxicamapproved, vet_approvedPhase 38171125-38-75281106, 54677470
Synonyms:
(3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
133687-22-6
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
71125-38-7
AC-1325
AC1NQY12
AC1Q3XZW
AKOS000279442
Abbott brand of meloxicam
Almirall brand of meloxicam
Apo-meloxicam
Bio-0826
Boehringer Ingelheim brand of meloxicam
C065757
C08169
C14H13N3O4S2
CCRIS 9139
CHEMBL599
CID5281106
Co Meloxicam
D00969
DB00814
Dom-meloxicam
Europharma brand of meloxicam
FT-0082769
Gen-meloxicam
HMS1922D19
HMS2089B18
I06-0490
LS-40538
M1959
Masflex
 
Meloxicam
Meloxicam (JAN/USAN/INN)
Meloxicam [USAN:BAN:INN]
Meloxicamum
Meloxicamum [Latin]
Meloxicamum [latin]
Meloxivet
Metacam
Mobec
Mobic
Mobic (TN)
Mobic, Metacam, Parocin, Meloxicam
Mobicox
MolPort-002-885-839
Movalis
Movatec
Movicox
Méloxicam
Novo-meloxicam
PHL-meloxicam
PMS-meloxicam
Parocin
Promeco brand of meloxicam
Ratio-meloxicam
S1734_Selleck
SPECTRUM1504150
STK620505
Squibb brand of meloxicam
TL8005001
Tenaron
UH-AC 62XX
UHAC-62XX
UNII-VG2QF83CGL
UNII-vg2qf83cgl
Uticox
meloxicam
miloxicam
reumoxicam
32
ZidovudineapprovedPhase 2, Phase 3, Phase 149530516-87-135370
Synonyms:
-Azido-3&prime
-deoxythymidine
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3&prime
3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
3'-azido-3'-deoxythymidine, AZT
3-Azido-3-deoxythymidine
30516-87-1
399024-19-2
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & SST
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT (Antiviral)
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT+PRO 140
AZT, Antiviral
Antiviral AZT
Apo-Zidovudine
Azidothymidine
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW A509U
BW-A 509U
BW-A-509U
BW-A509U
BWA 509U
BWA-509U
BWA509U
C07210
CCRIS 105
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
 
CPD000058351
Compound S
Cpd S
D00413
D015215
DB00495
DRG-0004
DS-4152 & AZT
DivK1c_000524
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
LS-1159
Liposomal AZT-SN-1
Liposomal AZT-SN-3
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
NSC 602670
Novo-Azt
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
Retrovir
Retrovir (TN)
Retrovir(TM)
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
SPECTRUM1502109
STK801891
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
Spectrum_001348
UNII-4B9XT59T7S
ZDV
ZIDOVUDINE [AZT]
ZINC03779042
ZVD
Zidovudin
Zidovudina
Zidovudina [Spanish]
Zidovudine (JAN/USP/INN)
Zidovudine EP III
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
antiviral
azidodeoxythymidine
rIFN-beta seron & AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
zidovudin
zidovudine
33
Abacavirapproved, investigationalPhase 2, Phase 3214136470-78-565140, 441300
Synonyms:
(+/-)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
(+/-)-Abacavir
(1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
136470-78-5
1592U89
168146-84-7
ABC
AC1L9AXG
Abacavir (INN)
Abacavir [INN]
Bio-0001
C07624
CHEBI:421707
 
CHEMBL1380
CID441300
D07057
DB01048
Epzicom
NCGC00164560-01
NCGC00164560-02
NSC742406
Trizivir
ZINC02015928
Ziagen
Ziagen (TM)(*Succinate salt*)
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol
abacavir
{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
34
DaunorubicinapprovedPhase 3, Phase 127320830-81-330323
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
AI3-52942
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Antibiotics from Streptomyces coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
CHEBI:41977
CHEMBL178
CID30323
Cerubidin
Cerubidine
D07776
DAUNORUBICIN HCL
DB00694
DM1
Daunamycin
Daunarubicinum
Dauno-Rubidomycine
DaunoXome
DaunoXome (TN)
Daunoblastin
Daunoblastine
Daunomycin
 
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
Daunorubicin Hcl
Daunorubicin Hydrochloride
Daunorubicin [INN:BAN]
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
Daunoxome
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
LMPK13050002
LS-187381
LS-997
Leukaemomycin C
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NCI-C04693
NChemBio.2007.10-comp14
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
RCRA waste no. U059
RP 13057
Rcra Waste No. U059
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
daunorubicin
nchembio723-comp2
35
EtoposideapprovedPhase 3, Phase 2, Phase 1126933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
36
Prednisoneapproved, vet_approvedPhase 3, Phase 2, Phase 1139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
37Cyclooxygenase 2 InhibitorsPhase 3624
38Albumin-Bound PaclitaxelPhase 3, Phase 22864
39Peripheral Nervous System AgentsPhase 3, Phase 2, Phase 123689
40Cyclooxygenase InhibitorsPhase 32870
41Topoisomerase InhibitorsPhase 3, Phase 2, Phase 15069
42Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 15602
43Antibiotics, AntitubercularPhase 3, Phase 2, Phase 17180
44Antimitotic AgentsPhase 3, Phase 2, Phase 15657
45AnalgesicsPhase 3, Phase 2, Phase 111733
46Anti-Bacterial AgentsPhase 3, Phase 2, Phase 111226
47Antirheumatic AgentsPhase 3, Phase 2, Phase 110956
48Anti-Inflammatory AgentsPhase 3, Phase 2, Phase 110729
49Anti-Inflammatory Agents, Non-SteroidalPhase 3, Phase 1, Phase 24443
50Analgesics, Non-NarcoticPhase 3, Phase 2, Phase 16501

Interventional clinical trials:

(show top 50)    (show all 163)
idNameStatusNCT IDPhase
1HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXTCompletedNCT00380770Phase 4
2Anti-Retrovirals for Kaposi's SarcomaCompletedNCT00444379Phase 4
3Organ Transplant Infection Prevention and Detection ProjectCompletedNCT00177801Phase 4
4Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's DiseaseWithdrawnNCT00361933Phase 4
5A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's SarcomaUnknown statusNCT00002318Phase 3
6TB-IRIS NSAID Cox-2 Inhibitor Prevention TrialUnknown statusNCT02060006Phase 3
7Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's SarcomaCompletedNCT00003350Phase 3
8A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in ZimbabweCompletedNCT00834457Phase 2, Phase 3
9Doxorubicin in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002985Phase 3
10A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00002319Phase 3
11Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.CompletedNCT00002147Phase 3
12Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS PatientsCompletedNCT00002445Phase 3
13Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00002105Phase 3
14A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00000994Phase 3
15A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.CompletedNCT00002093Phase 3
16Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KSRecruitingNCT01435018Phase 3
17Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's SarcomaActive, not recruitingNCT01352117Phase 3
18Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of PrednisoneActive, not recruitingNCT01924286Phase 3
19A Study of Selumetinib in Patients With Kaposi's SarcomaUnknown statusNCT01752569Phase 1, Phase 2
20Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's SarcomaUnknown statusNCT00003419Phase 2
21Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast CancerUnknown statusNCT00622466Phase 2
22Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's SarcomaCompletedNCT01067690Phase 2
23Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral CavityCompletedNCT01296815Phase 2
24Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug IndinavirCompletedNCT00362310Phase 2
25Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00064142Phase 2
26Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative PatientsCompletedNCT00055237Phase 2
27Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00019188Phase 1, Phase 2
28Lenalidomide in Treating Patients With AIDS-Associated Kaposi's SarcomaCompletedNCT01057121Phase 1, Phase 2
29BMS-275291 in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00024024Phase 1, Phase 2
30Nicotine Skin Patch in Treating Patients With Kaposi's SarcomaCompletedNCT00295984Phase 2
31Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00090987Phase 2
32SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00005042Phase 2
33Thalidomide in Treating Patients With HIV-Associated Kaposi's SarcomaCompletedNCT00019123Phase 2
34Paclitaxel in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00003008Phase 2
35Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV InfectionCompletedNCT00019240Phase 2
36Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00020449Phase 2
37Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CTCompletedNCT02201420Phase 2
38A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's SarcomaCompletedNCT02029430Phase 2
39Suppression of Oral HHV8 Shedding With ValganciclovirCompletedNCT00194467Phase 2
40A Study of ALRT1057 in Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002188Phase 2
41A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's SarcomaCompletedNCT00002131Phase 2
42A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002212Phase 2
43The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's SarcomaCompletedNCT00002366Phase 2
44Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's SarcomaCompletedNCT00002259Phase 2
45SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to TreatmentCompletedNCT00005931Phase 2
46The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's SarcomaCompletedNCT00001114Phase 2
47Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.CompletedNCT00002167Phase 2
48A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's SarcomaCompletedNCT00002314Phase 2
49A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00000996Phase 2
50Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton PharmaceuticalsCompletedNCT00002189Phase 2

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

About this section

Anatomical Context for Kaposi Sarcoma

About this section

MalaCards organs/tissues related to Kaposi Sarcoma:

36
Lung, Lymph node, Skin, Prostate, Liver, Heart, T cells

Publications for Kaposi Sarcoma

About this section

Articles related to Kaposi Sarcoma:

(show top 50)    (show all 356)
idTitleAuthorsYear
1
Acral pseudolymphomatous angiokeratoma of children with rainbow pattern: A mimicker of Kaposi sarcoma. (28087020)
2017
2
Is acquired arterial-venous fistula related to Kaposi sarcoma? (28214029)
2017
3
Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition. (28424322)
2017
4
RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. (28046107)
2017
5
Recombinant parvoviruses armed to deliver CXCL4L1 and CXCL10 are impaired in their antiangiogenic and antitumoral effects in a Kaposi sarcoma tumor model due to the chemokines' interference with the virus cycle. (28042949)
2017
6
Kaposi sarcoma, oral malformations, mitral dysplasia, and scoliosis associated with 7q34-q36.3 heterozygous terminal deletion. (28488400)
2017
7
Hepatic Kaposi sarcoma: A case report and review of the literature. (28217255)
2017
8
Kaposi Sarcoma in a patient treated with Ruxolitinib. (28419187)
2017
9
Kaposi Sarcoma and Lung Transplant: Two Case Reports. (28501344)
2017
10
Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency. (28430817)
2017
11
Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. (28394855)
2017
12
Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet Laser: A Preliminary Study. (28157730)
2017
13
Pulmonary Kaposi Sarcoma with Osseous Metastases in an Human Immunodeficiency Virus (HIV) Patient: A Remarkable Response to Highly Active Antiretroviral Therapy. (28216610)
2017
14
Classic Kaposi sarcoma in an HIV-negative Han Chinese man: a case report. (28329475)
2017
15
Topical diphencyprone for Kaposi sarcoma. (28133860)
2017
16
BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV. (28404899)
2017
17
mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi Sarcoma. (28506734)
2017
18
Increasing Numbers of New Kaposi Sarcoma Diagnoses in HIV-Infected Children and Adolescents Despite the Wide Availability of Antiretroviral Therapy in Malawi. (28077522)
2017
19
Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel. (27986137)
2017
20
Comparison of Kaposi sarcoma risk in HIV-positive adults across five continents: a multiregional multicohort study. (28531260)
2017
21
A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. (28341759)
2017
22
Pulmonary Kaposi sarcoma presenting as complete lung consolidation. (28331023)
2017
23
Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection. (27770395)
2017
24
Lymphangioma-like classic Kaposi sarcoma. (28188608)
2017
25
Ultraviolet Radiation and Kaposi Sarcoma Incidence in a Nationwide US Cohort of HIV-Infected Men. (28040691)
2017
26
Acquired Immune Deficiency Syndrome-Associated Kaposi Sarcoma in a Child Presenting as a Solitary Plantar Hyperkeratotic Plaque. (28288525)
2017
27
A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura. (27885868)
2017
28
Diagnosis and Treatment of Kaposi Sarcoma. (28324233)
2017
29
Kaposi sarcoma: an unusual cause of gastrointestinal bleeding. (26896679)
2016
30
Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. (27578823)
2016
31
Asymptomatic Pulmonary Allograft Kaposi Sarcoma: A Case Report. (26767437)
2016
32
A prospective ascertainment of cancer incidence in sub-Saharan Africa: The case of Kaposi sarcoma. (26823008)
2016
33
Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study. (27082863)
2016
34
Pulmonary Kaposi Sarcoma: An Uncommon Cause of Respiratory Failure in the Era of Highly Active Antiretroviral Therapy-Case Report and Review of the Literature. (27872774)
2016
35
Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS. (26811480)
2016
36
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. (27662664)
2016
37
Hepatic Kaposi Sarcoma Revisited: An Important but Less Commonly Seen Neoplasm in Patients With Acquired Immunodeficiency Syndrome. (27984514)
2016
38
Asymmetric relapse of an HIV-associated Kaposi sarcoma. (27832310)
2016
39
Severe Kaposi Sarcoma in an Urban Public Hospital. (28019110)
2016
40
Primary effusion lymphoma and concurrent progressive Kaposi sarcoma associated with elevated interleukin-6. (28092896)
2016
41
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. (27584730)
2016
42
Kaposi sarcoma herpesvirus-associated disorders and related diseases. (27662501)
2016
43
Genotypic distribution of HHV-8 in AIDS individuals without and with Kaposi sarcoma: Is genotype B associated with better prognosis of AIDS-KS? (27902590)
2016
44
Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function. (27893813)
2016
45
Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma. (27996149)
2016
46
Non-AIDS Kaposi sarcoma in the external ear. (27370401)
2016
47
Kaposi Sarcoma among HIV Infected Patients in Lagos University Teaching Hospital, Nigeria: A 14-Year Retrospective Clinicopathological Study. (27034839)
2016
48
Mapping the Epidemiology of Kaposi Sarcoma and Non-Hodgkin Lymphoma Among Children in Sub-Saharan Africa: A Review. (27082516)
2016
49
Kaposi Sarcoma of the Plantar Surface. (27432041)
2016
50
Identification of Kaposi Sarcoma Herpesvirus (KSHV) vIRF1 Protein as a Novel Interaction Partner of Human Deubiquitinase USP7. (26786098)
2016

Variations for Kaposi Sarcoma

About this section

Cosmic variations for Kaposi Sarcoma:

8
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM575NRASsoft tissue,skin,sarcoma,NSc.38G>Cp.G13A65
2COSM520KRASsoft tissue,lung,sarcoma,NSc.35G>Tp.G12V65
3COSM521KRASbiliary tract,gallbladder,other,hyperplasiac.35G>Ap.G12D6
4COSM517KRASbiliary tract,gallbladder,other,hyperplasiac.34G>Ap.G12S6

Expression for genes affiliated with Kaposi Sarcoma

About this section
Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for genes affiliated with Kaposi Sarcoma

About this section

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 43)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
10.0IL6, IL6R, IL6ST
2
Show member pathways
10.0IL6, IL6R, IL6ST
3
Show member pathways
10.0IL6, IL6R, IL6ST
410.0IL6, IL6R, IL6ST
510.0IL6, IL6R, VEGFA
610.0IL6, IL6R, VEGFA
710.0FGF2, KDR, VEGFA
8
Show member pathways
10.0FGF2, KDR, VEGFA
910.0FGF2, KDR, VEGFA
1010.0FGF2, FGF4, VEGFA
11
Show member pathways
10.0FGF2, FLT4, KDR
1210.0IL6ST, OSM, VEGFA
1310.0IFNA1, IFNA2, IL6
14
Show member pathways
10.0FLT4, KDR, VEGFA
15
Show member pathways
10.0FLT4, KDR, VEGFA
1610.0CD34, IFNA2, IL6
17
Show member pathways
10.0FGF2, FGF4, FGF5
18
Show member pathways
10.0FGF2, FGF4, FGF5
1910.0FGF2, FGF4, FGF5
209.9CD34, IL6, IL6R
21
Show member pathways
9.8IL6, IL6R, IL6ST, OSM
229.8CD34, FGF2, FGF4, IL6
239.7FGF2, FGF4, IL6, IL6R, VEGFA
249.7FGF2, IL6, IL6R, OSM, VEGFA
259.7FGF2, FGF4, IL6, KDR, VEGFA
269.7IFNA1, IFNA2, IL6, IL6R, IL6ST
279.5CDK6, FGF2, FGF4, FGF5, IL6, VEGFA
28
Show member pathways
9.5FGF2, FGF4, FGF5, FLT4, IL6, KDR
29
Show member pathways
9.5FGF2, FGF4, FGF5, FLT4, IL6, KDR
30
Show member pathways
9.5FGF2, FGF4, FGF5, FLT4, IL6, KDR
31
Show member pathways
9.5FGF2, FGF4, FGF5, FLT4, KDR, VEGFA
32
Show member pathways
9.5FGF2, FGF4, FGF5, FLT4, KDR, VEGFA
33
Show member pathways
9.4IFNA1, IFNA2, IL6, IL6R, IL6ST, OSM
34
Show member pathways
9.3FGF2, FGF4, FGF5, FLT4, IL6, KDR
35
Show member pathways
9.0CDK6, FGF2, FGF4, FGF5, FLT4, IL6
36
Show member pathways
8.8CCR8, FGF2, FGF4, FGF5, FLT4, IL6
37
Show member pathways
8.8CCR8, FGF2, FGF4, FGF5, FLT4, IL6
38
Show member pathways
8.8FGF2, FGF4, FGF5, IFNA1, IFNA2, IL6
39
Show member pathways
8.8FGF2, FGF4, FGF5, FLT4, IFNA1, IFNA2
40
Show member pathways
8.7CCR8, FLT4, IFNA1, IFNA2, IL6, IL6R
41
Show member pathways
8.5CCR8, CDK6, FGF2, FGF4, FGF5, FLT4
428.4CDK6, FGF2, FGF4, FGF5, FLT4, IFNA1
43
Show member pathways
8.4CD34, FGF2, FGF4, FGF5, IFNA1, IFNA2

GO Terms for genes affiliated with Kaposi Sarcoma

About this section

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ciliary neurotrophic factor receptor complexGO:007011010.9IL6R, IL6ST
2external side of plasma membraneGO:000989710.5CD34, IL6, IL6ST, PDPN
3interleukin-6 receptor complexGO:000589610.0IL6, IL6R, IL6ST
4extracellular regionGO:00055768.2CD34, FGF2, FGF4, FGF5, FLT4, IFNA1

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 46)
idNameGO IDScoreTop Affiliating Genes
1hepatic immune responseGO:000238410.9IL6, IL6R
2ciliary neurotrophic factor-mediated signaling pathwayGO:007012010.9IL6R, IL6ST
3chondroblast differentiationGO:006059110.9FGF2, FGF4
4negative regulation of hormone secretionGO:004688810.9IL6, OSM
5oncostatin-M-mediated signaling pathwayGO:003816510.9IL6ST, OSM
6positive regulation of leukocyte chemotaxisGO:000269010.9IL6, IL6R
7positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathwayGO:003803310.9KDR, VEGFA
8lymphangiogenesisGO:000194610.8FLT4, PDPN
9positive regulation of protein kinase C signalingGO:009003710.8FLT4, VEGFA
10endothelium developmentGO:000315810.8CD34, KDR
11positive regulation of cellular component movementGO:005127210.8PDPN, VEGFA
12positive regulation of positive chemotaxisGO:005092710.8KDR, VEGFA
13interleukin-6-mediated signaling pathwayGO:007010210.8IL6, IL6R, IL6ST
14cell migration involved in sprouting angiogenesisGO:000204210.8FGF2, KDR, VEGFA
15positive regulation of acute inflammatory responseGO:000267510.7IL6, IL6ST, OSM
16cellular response to vascular endothelial growth factor stimulusGO:003592410.7FLT4, KDR, VEGFA
17humoral immune responseGO:000695910.7IFNA1, IFNA2, IL6
18fibroblast growth factor receptor signaling pathwayGO:000854310.7FGF2, FGF4, FGF5
19regulation of endothelial cell chemotaxis to fibroblast growth factorGO:200054410.7FGF2, FGF4
20positive regulation of osteoblast differentiationGO:004566910.7IL6, IL6R, IL6ST
21phosphatidylinositol phosphorylationGO:004685410.7FGF2, FGF4, FGF5
22phosphatidylinositol-3-phosphate biosynthetic processGO:003609210.7FGF2, FGF4, FGF5
23positive regulation of endothelial cell migrationGO:001059510.7FLT4, KDR, VEGFA
24positive regulation of vasculogenesisGO:200121410.7CD34, KDR
25positive regulation of peptidyl-serine phosphorylationGO:003313810.7IL6, OSM, VEGFA
26stem cell proliferationGO:007208910.6CD34, FGF2
27angiogenesisGO:000152510.6FGF2, FLT4, KDR, VEGFA
28positive regulation of endothelial cell proliferationGO:000193810.5FGF2, FLT4, KDR, VEGFA
29response to cytokineGO:003409710.5IL6, IL6R, IL6ST
30regulation of phosphatidylinositol 3-kinase signalingGO:001406610.5FGF2, FGF4, FGF5
31positive regulation of angiogenesisGO:004576610.5CD34, FGF2, KDR, VEGFA
32positive regulation of peptidyl-tyrosine phosphorylationGO:005073110.5IL6, IL6R, OSM, VEGFA
33positive regulation of MAPK cascadeGO:004341010.5FLT4, IL6, KDR, OSM
34cytokine-mediated signaling pathwayGO:001922110.4IFNA1, IFNA2, IL6, IL6R, IL6ST
35positive regulation of protein phosphorylationGO:000193410.4FGF4, FLT4, KDR, VEGFA
36positive regulation of ERK1 and ERK2 cascadeGO:007037410.4FGF2, FGF4, FLT4, IL6, KDR
37regulation of cell shapeGO:000836010.4IL6, KDR, PDPN, VEGFA
38peptidyl-tyrosine phosphorylationGO:001810810.4FGF2, FGF4, FGF5, FLT4, KDR
39positive regulation of cell divisionGO:005178110.3FGF2, FGF4, FGF5, OSM, VEGFA
40positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.3IFNA2, IL6, IL6R, IL6ST, OSM
41positive regulation of gene expressionGO:001062810.3CD34, CDK6, FGF4, IL6, VEGFA
42negative regulation of apoptotic processGO:004306610.3FGF4, FLT4, IL6, IL6ST, KDR, VEGFA
43positive regulation of tyrosine phosphorylation of STAT proteinGO:004253110.2IFNA2, IL6, IL6R, IL6ST, OSM, VEGFA
44vascular endothelial growth factor receptor signaling pathwayGO:004801010.1FLT4, KDR, VEGFA
45vascular endothelial growth factor signaling pathwayGO:003808410.1FLT4, KDR
46positive regulation of cell proliferationGO:00082849.5FGF2, FGF4, FGF5, FLT4, IL6, IL6R

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1ciliary neurotrophic factor receptor activityGO:000489710.8IL6R, IL6ST
2interleukin-6 bindingGO:001998110.8IL6R, IL6ST
3interleukin-6 receptor activityGO:000491510.8IL6R, IL6ST
41-phosphatidylinositol-3-kinase activityGO:001630310.6FGF2, FGF4, FGF5
5interleukin-6 receptor bindingGO:000513810.6IL6, IL6R, IL6ST
6fibroblast growth factor receptor bindingGO:000510410.6FGF2, FGF4, FGF5
7growth factor bindingGO:001983810.6FLT4, IL6ST, KDR
8phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.5FGF2, FGF4, FGF5
9vascular endothelial growth factor-activated receptor activityGO:000502110.1FLT4, KDR
10cytokine activityGO:000512510.1FGF2, IFNA1, IFNA2, IL6, OSM, VEGFA
11growth factor activityGO:000808310.1FGF2, FGF4, FGF5, IL6, OSM, VEGFA
12protein tyrosine kinase activityGO:00047139.8FGF2, FGF4, FGF5, FLT4, KDR

Sources for Kaposi Sarcoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet